Inappropriate sinus tachycardia (IST) is an incompletely understood condition characterised by an elevation in heart rate (HR) accompanied by wide ranging symptoms, in the absence of an underlying physiological stimulus. The condition often takes a chronic course with significant adverse effects on quality of life. Currently there is no effective treatment for IST.
Introduction
Inappropriate sinus tachycardia is defined as a persistent non-paroxysmal elevation in the resting and exertional HR with no identifiable physiological or pathological stimulus (1) .
There is no formally accepted HR threshold for the definition of IST. This is, in part, related to the wide range of normal HR variation within the population, its dependency on age (2) and underlying physiological status. Population studies show that, in addition to an inverse correlation with age, mean intrinsic HR (HR under complete pharmacologic autonomic blockade or autonomic denervation) is independently associated with levels of physical activity, blood pressure, tobacco smoking, intake of caffeine and body height (3) . The 2015
Heart Rhythm Society expert consensus statement defines IST as a "sinus heart rate >100bpm at rest (with a mean 24-hour heart rate >90 bpm not due to primary causes) and associated distressing symptoms of palpitations" (1, 4, 5) . Other commonly described symptoms include dizziness, light headedness, dyspnoea and pre-syncope.
Prevalence and Clinical Course of IST
An Icelandic study of randomly sampled patients from insurance registries for hypertension reimbursement, described the prevalence and course of IST using the above definition(4).
The largest of its kind, the study rigorously excluded differential diagnoses and mimics of the condition. However, the overall population was relatively small (604) and 149 subjects were on beta adrenoceptor antagonists for hypertension treatment. Of the 604 patient cohort, 7 fulfilled the definition for IST, yielding a prevalence of 1.16%. This is greater than the estimates for Wolff-Parkinson-White syndrome (0.15-0.31%) (6) 
. No differences were
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found between IST and control patients with regards to age, gender, smoking habits, alcohol intake, physical activity levels and adiposity. The mean age and 24-h ambulatory systolic pressure in the IST group was 47±7 years and 147±11 mmHg, respectively, noting the likely bias related to the cohort source (systemic arterial hypertension). After a mean follow-up of 6.0±2.4 years, the outlook for the condition was found to be benign, particularly for the development of tachycardia-mediated cardiomyopathy and survival. However, at follow-up, there was persistence of symptoms, elevated resting HR and elevated average daily HR.
Mechanisms in IST
The trigger and mechanism for the tachycardia in IST is unknown. Expert anecdotal evidence has suggested halogenated hydrocarbon exposure as one possible cause, although this is unsubstantiated (7) . Peripheral and central neurohormonal mediators of autonomic control or their receptors have been implicated, however this remains speculative (8, 9) . Notably, an exaggerated HR response to isoprenaline infusion occurs in less than one third of patients (10) . This observation and the relative inefficacy of beta-blockade have led some investigators to believe that the condition may represent a sinus node channelopathy rather than an abnormality of autonomic modulation (11) . Some clinical studies have pointed towards an elevation in intrinsic HR mediated by ATP sensitive potassium channels in sinus node tissue (12) . A small study has identified greater plasma levels of beta adrenoceptor antibodies in patients with IST as compared to controls (11) . The presence of these antibodies has been hypothesised to result in receptor activation function and second messenger mediated calcium influx and depolarisation. As yet there have been no reports of specific genetic abnormalities associated with IST.
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Clinical Presentation and Diagnosis
Inappropriate sinus tachycardia often presents non-specifically with symptoms including pre-syncope, syncope, dyspnoea, exercise intolerance, dizziness, light-headedness, weakness and palpitations either chronically or in a relapsing and remitting pattern. Their severity may vary from mild to significantly disabling, and importantly may not parallel the severity of the tachycardia.
Essential to the diagnosis of IST is exclusion of underlying causes for an appropriate sinus tachycardia such as anaemia, cardiac failure, infection, stimulant intake, thyrotoxicosis, anxiety or psychosis. Therefore, in addition to undertaking a thorough general medical assessment, laboratory (serum thyrotropin levels and full blood count) tests, a 12-lead ECG and ambulatory cardiac rhythm monitors are required. The latter may be in the form of 24-hour, 48-hour, 7-day or longer ambulatory monitors which may reveal occult arrhythmias or allude to non-physiological phenomena such as lack of nocturnal vagal predominance. In accordance with expert consensus, the clinical diagnosis is made, after exclusion of differentials, in symptomatic patients with a persisting daytime sinus tachycardia 
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ECG in AVNRT is usually normal at baseline and subtle retrograde conducted P-waves are often seen during SVT. Accessory pathways may result in typical delta waves and short PR duration at baseline if conducting in the anterograde direction, and therefore it is manifest.
Generally, if the accessory pathway conducts in the retrograde direction, features of preexcitation are absent at baseline, and therefore it is concealed. Accessory pathway mediated SVT may be broad or narrow QRS complex, depending on the directionality of pathway conduction during SVT. One important pre-excitation syndrome mostly affecting children and teenagers is the permanent form of reciprocating junctional tachycardia (PJRT).
This incessant form of long RP SVT commonly utilises an accessory pathway which is located in the right inferior paraseptal region and is often drug refractory. Its chronic nature and tachycardia rates as low as 130bpm may mask the diagnosis for months and subsequently promote a tachycardia-mediated cardiomyopathy. The latter is reversible after accessory pathway ablation (13) (14) .
Atrial tachycardia (AT) on the other hand may oftentimes be difficult to differentiate from IST, particularly when arising from areas adjacent to the sinus node, such as superior crista terminalis or even within the sinus node in the form of re-entry. Although 12-lead ECG P wave axis and morphology will often provide vital clues to the AT site of origin, an AT focus close to the sinus node will generate a P wave morphology very similar or identical to that of sinus rhythm. The onset of tachycardia and symptoms, in addition to other clinical features, may point to either IST or AT.
Another condition to consider is Postural Orthostatic Tachycardia Syndrome (POTS), as both
POTS and IST have overlapping clinical features. This increasingly recognised disorder is a condition of autonomic dysfunction characterised by a hyperadrenergic response to
Accepted Article orthostatic change in posture, with symptoms of dizziness, pre-syncope and diaphoresis (15) . An exaggerated HR response to isoprenaline may be seen in both IST and POTS, and therefore a detailed clinical assessment is required to demonstrate the orthostatic relationship to symptoms and HR changes which occur in POTS. A head up tilt table test may be useful in demonstrating a 30 bpm HR rise (or tachycardia >120 bpm) on assuming the upright position from being supine. In the supine position, the 12-lead ECG in POTS patients is rarely >100 bpm whereas in IST the resting HR is often >100 bpm.
Conventional Management Strategies for IST
The use of negative chronotropic agents such as beta-blockers and calcium antagonists is often unsuccessful in controlling IST symptoms and HR(16). Intolerance to beta-blockade side effects may be particularly troublesome in this patient group. Clinicians have occasionally trialled beta adrenoceptor antagonists with intrinsic sympathetic activity (for example, pindolol or acebutolol). The goal with this approach is to supress elevated HR whilst minimising anti-adrenergic related adverse effects. However, there is no evidence supporting an advantage for beta-blockers with intrinsic sympathetic activity over pure beta-blockers. There is an identified overlap of IST in some instances with anxiety disorders, which may also require specific treatment(1).
Invasive techniques are reserved for patients highly debilitated by drug-refractory symptoms. Limited experience exists for surgical or radiofrequency catheter modification of the sinus node zone in these patients. The effectiveness of catheter ablation in IST is at best modest. At an experienced centre, after a mean follow-up of 4 months, symptoms recurred This article is protected by copyright. All rights reserved.
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in 27% of patients deemed to have acute procedural success (17) . Long term symptom control was not achieved in one third of patients despite repeat procedures. The risk of complications is low but not non-trivial. Sinus node dysfunction requiring permanent pacing, right phrenic nerve injury and superior vena cava syndrome are uncommon but serious complications.
The ablate and pace strategy is often undesirable in view of the sacrifice of atrio-ventricular conduction and complete reliance on permanent pacing in this younger demographic.
Ivabradine Overview of Ivabradine
Ivabradine is a novel selective inhibitor of cardiac ionic channels which results in negative chronotropic effects through a reduced sinoatrial depolarisation rate, with negligible effects on contractility. The agent has been approved in Australia since 2006 primarily as a second line agent for patients with chronic stable angina who are intolerant of, or have a contraindication to beta-blockers, or as add-on therapy to beta-blockers in patients with inadequately controlled HR. The drug has been studied for its quantitative impact on exercise tolerance in patients with coronary artery disease and for its role in the treatment of chronic systolic (impaired ejection fraction) heart failure (18) (19) (20) (21) (22) (23) . Currently, Ivabradine is only covered by the Pharmaceutical Benefit Scheme (PBS) for its use in Heart failure and although approved for use in angina, this is currently only as a private prescription. In addition, emerging evidence has shown ivabradine to be of potentially significant benefit in patients with IST (24) (25) (26) ).
This article is protected by copyright. All rights reserved. Ivabradine is a weak inhibitor of CYP3A4 and is therefore unlikely to influence metabolism of other drugs, or their plasma levels. Food delays absorption but increases peak plasma levels and overall bioavailability to 70%. Trough plasma levels occur 12 hours after the last dose and on that basis, clinical studies into its quantitative effect on exercise tolerance are performed at this nadir state.
Contra-indications and adverse reactions
Ivabradine is generally contraindicated in the presence of resting bradycardia (<60 bpm), hypotension, and in sinus node dysfunction. Atrioventricular (AV) nodal disease is a relative contraindication however the drug may be used with caution in first and second degree AV block. Due to the lack of clinical studies into its safety or efficacy in atrial or ventricular tachyarrhythmias, Ivabradine should generally be avoided in those conditions. Finally, in conditions that predispose to an acquired long QT interval, Ivabradine should be avoided or used with careful monitoring to prevent excessive bradycardia and exacerbation of the polymorphic ventricular tachycardia risk.
Ivabradine is shown to be well tolerated, with dose-dependent predictable adverse reactions. The most common cardiovascular adverse reactions are bradycardia and hypotension whereas visual disturbances are the most common non-cardiovascular effects.
Bradycardia (<60 bpm) was estimated at 4.2% in a randomised clinical study(31). This is comparable to but somewhat lower than the prevalence of bradycardia noted for the beta adrenoceptor antagonist, atenolol (5 
.8%). The combination of beta-blocker and Ivabradine
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use results in an additive risk of bradycardia, with the SIGNIFY study showing a prevalence of 17.9% in a randomised double-blind multi-centre clinical trial setting (19) . The most common adverse reaction overall is a phenomenon of visual phosphenes (14.5%) (27) . This consists of bright illuminations at the periphery of the visual field exacerbated by sudden changes in the ambient level of brightness. This peculiar effect appears to be benign with the vast majority of patients reporting a mild to moderate level of intensity. The condition is self-resolving in >75% of patients within a matter of months without dose modification or treatment interruption (27) . Less than 1% of patients reported having to stop treatment or modification of their daily activities to accommodate for this visual disturbance.
Role of Ivabradine in IST
With the development of ivabradine and insights into its pharmacologic mechanisms, some experimental use in IST has emerged (25) . Early pilot work demonstrated the effectiveness of Ivabradine in reducing minimum, mean and maximum HR in addition to symptom improvement or complete resolution (27) . In addition, the drug appeared to be well tolerated.
Several non-randomised open label studies of short to intermediate follow-up duration
showed scope for the efficacy and tolerability of Ivabradine in IST. In 2010, an open label efficacy study in 18 subjects showed the drug to be well tolerated and associated with a significant reduction in maximal and median HR as well as greater workloads achieved on standard treadmill stress testing. One patient was excluded from the study due to persistent phosphene visual effects despite dosage reduction (23) .
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In 2012 a small randomised and placebo controlled cross-over study compared Ivabradine to placebo in 21 patients with IST(28). After 6 weeks of therapy, patients taking Ivabradine 
Conclusion
Inappropriate sinus tachycardia is a condition with a best estimate prevalence of 1.16% in the general adult population. The condition has a wide spectrum of symptom severity and due to its predilection in the young, it has the potential to adversely impact daily activities, particularly effort tolerance and personal economic productivity, despite its overall benign course. Whilst it remains ill-defined on a cellular level, it appears that IST is probably a sinus node channelopathy in origin rather than a disease of altered autonomic modulation (as opposed to POTS, an important differential diagnosis). The mainstay of therapy has been beta-blockers. Despite some effect at reducing HR, these agents appear to have limited benefit and a significant adverse effect profile in this active younger group of patients. This results in an abbreviated PR interval and a delta wave (slurred QRS upstroke). D. An example of focal atrial tachycardia is shown. Like A, this is also a long RP tachycardia. The specific P wave morphology and polarity will depend on the precise location of the focus along the crista terminalis. This article is protected by copyright. All rights reserved. Table 1 : Symptoms assessed by SF36 and/or European Heart Rhythm Association symptom score grades (I-IV). Heart rate trends assessed by 24 hour Holter monitoring. Metoprolol tartarate is a rapid acting twice daily dosed beta-blocker,
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